top of page


Aptar Pharma acquires Pulmotree to expand next-generation pulmonary drug delivery technology
Aptar Pharma has acquired German inhalation technology specialist Pulmotree, adding its Kolibri platform to expand next-generation pulmonary drug delivery capabilities.

nuaxia
Oct 282 min read


Alcon acquires Neurotech Pharmaceuticals for $550 million to expand retinal disease portfolio
Alcon is acquiring Neurotech Pharmaceuticals for a reported $550 million, adding Encelto and an encapsulated-cell therapy platform to its retinal disease portfolio.

nuaxia
Oct 222 min read


Eli Lilly partners with METiS TechBio in AI-driven lipid nanoparticle collaboration worth up to $1.1 billion in milestones
Eli Lilly and METiS TechBio have entered an AI-enabled lipid nanoparticle discovery collaboration carrying up to approximately $1.1 billion in potential milestone payments.

nuaxia
Oct 212 min read


Eton licenses Aquestive's Libervant seizure rescue film for exclusive US commercialisation
Eton Pharmaceuticals has secured exclusive US commercialisation rights to Aquestive Therapeutics' Libervant diazepam buccal film for the investigational treatment of seizure clusters.

nuaxia
Oct 152 min read


SpyGlass Pharma acquires Advanced Vision Science for $13m to secure intraocular lens manufacturing
SpyGlass Pharma has acquired Advanced Vision Science for approximately $13 million, bringing manufacturing of a key intraocular lens used in its drug-delivery platform in-house.

nuaxia
Oct 21 min read


Novartis licenses Alteogen Hybrozyme technology for multiple subcutaneous products
The agreement gives Novartis options to secure exclusive rights to develop and commercialise multiple subcutaneous products using Alteogen's ALT-B4 Hybrozyme technology.

nuaxia
Sep 42 min read


FDA approves Yesintek single-dose autoinjector for chronic inflammatory diseases
The supplemental approval introduces a new self-injection option for patients receiving Yesintek across its approved autoimmune indications without changing the medicine's existing therapeutic uses.

nuaxia
Aug 212 min read


FDA approves Lerochol autoinjector and updates indication for monthly PCSK9 therapy
The new device provides adults with hypercholesterolaemia with an additional self-administration option for once-monthly Lerochol alongside the existing pre-filled syringe.

nuaxia
Aug 192 min read


Alteogen signs $365 million Hybrozyme licensing deal for subcutaneous biologic
The agreement gives an undisclosed global pharmaceutical company worldwide rights to use Alteogen’s ALT-B4 technology to develop and commercialise a subcutaneous formulation of an existing biologic.

nuaxia
Aug 72 min read


Sanofi’s Sarclisa Escena Receives FDA Approval as First Oncology Drug Delivered Through On-Body Injector
The FDA has approved Sarclisa Escena, a subcutaneous on-body injector formulation of Sanofi’s multiple myeloma therapy isatuximab, becoming the first cancer treatment authorised in the US for delivery through an on-body injector system. Sanofi has secured US Food and Drug Administration (FDA) approval for Sarclisa Escena, a new subcutaneous (SC) formulation of its multiple myeloma therapy Sarclisa (isatuximab-irfc) delivered through an on-body injector (OBI). The approval rep

nuaxia
Jul 133 min read
bottom of page